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INTRODUCTION
Dupuytren’s disease is an incurable proliferative dis-
order of the palmar fascia, characterized by the develop-
ment of palmar nodules and cords.1 Over time, the cords 
can contract and limit finger extension. Patients report a 
variable extent of functional impairment and diminished 
quality of life.2,3
Percutaneous needle aponeurotomy (PNA) and col-
lagenase clostridium histolyticum (CCH) have gained 
popularity as less-invasive treatment alternatives to lim-
ited fasciectomy—the current standard of care.4–7 With 
PNA, originally popularized by French rheumatologists, 
surgeons use a hypodermic needle to release cords at 
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similar improvements in the overall Michigan Hand Questionnaire score (PNA 5.3 
points versus CCH 4.9 points; P = 0.912).
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effective as PNA in reducing contractures. Both treatments were safe and im-
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multiple levels after which the affected finger is extended 
to improve contracture. With CCH, which selectively dis-
solves collagen, a small volume of collagenase solution is 
injected into the cords. This weakens the treated areas, 
allowing for subsequent release through forceful manip-
ulation. To date, 2 randomized clinical trials have com-
pared the 2 techniques, both reporting that their efficacy 
is comparable.8,9 Nevertheless, the extent to which these 
results can be translated into clinical practice remains in-
completely understood because the controlled conditions 
in such trials may not reflect clinical practice. Patients’ 
choices, selection, and compliance with treatment regi-
mens in trials can differ substantially from that in actual 
practice, resulting in a discrepancy in the results achieved 
in trials versus those in practice.10–12
The aim of this study was to compare the outcomes 
of PNA and CCH in daily practice using data gathered at 
multiple practice sites in the Netherlands. We studied the 
impact of both treatments on the degree of contracture, 
different domains of hand function, and associated ad-
verse effects.
METHODS
Study Design
This is a study of data compiled from 2 previous com-
parative studies4,13 performed between 2011 and 2014 at 
7 hand surgery practice sites in the Netherlands, includ-
ing 1 academic institution and a consortium of 6 dedi-
cated hand surgery sites. Briefly, patients were eligible if 
they were adults with a diagnosis of primary or recurrent 
Dupuytren’s disease, underwent PNA or CCH, and had 
contractures affecting the MCP and/or proximal inter-
phalangeal (PIP) joints. Patients were excluded if they un-
derwent treatment for a concomitant hand condition that 
could confound outcomes assessments (e.g., carpal tun-
nel release). For this study, we also excluded patients who 
underwent simultaneous treatment for multiple digits to 
increase comparability between the groups. Our local in-
stitutional review board exempted this study from formal 
review due to the retrospective nature of this study.
Procedures
Treatments were performed as part of standard clinical 
practice by the surgeons of the participating practice sites. 
Hence, treatment selection occurred through shared-de-
cision making.
PNA was performed under local anesthesia. Cords 
were released using 25 gauge needles at as many levels as 
possible in the palm and fingers. Patients were instructed 
to report paresthesias to avoid nerve injury. After release, 
the treated digit was extended with a progressive force to 
maximize correction. Patients were encouraged to flex 
and extend their digits immediately following treatment 
and to restart normal use of their hands after 24 hours.
CCH was administered according to manufacturer 
instructions, without local anesthesia. Injections were 
limited to 0.25 mL and 0.20 mL for MCP and PIP joint con-
tractures, respectively. Afterward, compressive dressings 
were applied. Treated digits were manipulated after 24–72 
hours to attempt release of the weakened cords under lo-
cal anesthesia. Up to 3 injections were offered at 4-week 
intervals if patients were dissatisfied with the achieved lev-
el of correction but were not mandatory. All patients were 
offered a similar rehabilitation and splinting program as 
patients undergoing PNA.
Outcome Measures
The primary outcome was early improvement in de-
gree of contracture. The degree of contracture (active ex-
tension deficit) was assessed by certified hand therapists 
using a finger goniometer before treatment and at visits 
occurring between 6–12 weeks after surgery or the last in-
jection. Any hyperextension was defined as 0° to prevent 
underestimation of total extension deficit. At the same vis-
its, adverse effects were noted, which were divided based 
on their severity into 2 categories: serious (nontransient 
or requiring an intervention) and mild (transient or not 
requiring an intervention).
Finally, we examined the impact of both treatments 
on different aspects of hand function using the Michigan 
Hand outcomes Questionnaire (MHQ).14 Because we as-
sumed that some patients would require at least 6 months 
for full functional recovery after treatment, we asked pa-
tients to complete the MHQ before and between 6 months 
and 1 year after treatment. The MHQ consists of 37 items 
evaluating 6 subdomains for each hand separately: over-
all hand function, ability to perform activities in daily life, 
work performance, hand appearance, pain, and satisfac-
tion with hand function. The fact that the MHQ includes 
a subdomain assessing hand appearance increases its 
scope15 and makes it particularly well-suited for some pa-
tients with Dupuytren’s contracture.16,17 Scores range from 
0 to 100 (with 100 indicating best hand performance). As 
this study was directed at assessing improvement in con-
tracture rather than pain reduction, we excluded all pain-
related outcomes. We only used the outcomes pertaining 
to the treated side.
Propensity-Score Matching
In practice, the choice between PNA versus CCH is 
not random but related to clinical factors, such as the de-
gree of contracture and patient characteristics, as a conse-
quence of differences in patient selection and preference. 
Therefore, we expected that the PNA and CCH groups 
would differ with respect to their baseline characteris-
tics. To account for such differences that can otherwise 
threaten the validity of a comparison due to treatment 
selection bias, we applied propensity score matching.18,19 
This approach has been used previously to examine the 
comparative effectiveness of treatments for Dupuytren’s 
contracture, including PNA and CCH.4,13
Propensity scores for the probability of undergoing 
CCH and PNA were developed using a logistic regres-
sion model with the following baseline characteristics as 
explanatory variables: age,20 gender,21 family history of 
the disease,22 primary or recurrent disease,23 the baseline 
degree of contracture24 at the MCP, PIP, and distal inter-
phalangeal joint levels, and which joints were affected.25 
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These variables were included because they were consid-
ered related to (1) either the choice between CCH or PNA 
or (2) clinical outcomes. After calculating the individual 
scores, we attempted to match each patient from the PNA 
group with 2 patients from the CCH group with the closest 
propensity scores (i.e., who had the most similar charac-
teristics) using a nearest-neighbor algorithm with replace-
ment. We repeated this process until matches had been 
attempted for all patients from the PNA group. To exam-
ine whether propensity score matching improved similar-
ity among the treatment groups, significance testing was 
performed before and after matching.
Statistical Analysis
Sample size calculations estimated that a total 32 affect-
ed MCP joints (16 each group) and 70 proximal interpha-
langeal contractures (35 each group) would provide 80% 
power to detect a 10-degree difference in contracture be-
tween the 2 treatment groups with the use of 2-sided tests.4
For improvement in contracture (both in percent-
age and in absolute degrees) and MHQ scores, we used 
Student t tests to compare the change at follow-up from 
baseline between treatment groups with corresponding 
means and 2 standard errors plotted graphically. The pro-
portion of joints with clinical improvement, defined as 
improvement of ≥ 50% in the degree of contracture, was 
compared with Chi-square tests. Outcomes were analyzed 
separately for affected MCP and PIP joints because results 
at the PIP joint are typically worse. Rates of adverse effects 
were compared using the Chi-square or Fisher’s exact test 
if effects occurred in both treatment groups.
Continuous variables were reported as means ± SD and 
categorical variables with the use of frequencies. P values of 
< 0.05 were considered to indicate statistical significance.
RESULTS
Study Sample
There were a total of 183 patients of whom 79 under-
went PNA and 104 CCH. After excluding 28 patients who 
were treated with PNA for multiple digits, a total of 155 
eligible patients remained: 51 underwent PNA and 104 
underwent CCH (Fig. 1).
Differences between the PNA and CCH groups before 
propensity score matching included that patients un-
dergoing CCH were more often men, were, on average, 
younger, had less total extension deficit, and proportion-
ally fewer affected MCP joints (Table 1, left). This further 
highlights the need to account for these differences be-
fore comparing the 2 groups since all these factors have 
been previously found to influence outcomes.21–24 At the 
same time, all remaining characteristics were not signifi-
cantly different, showing that the indications for CCH 
and PNA were not substantially different at the participat-
ing sites.
With the use of propensity scores, we were able to 
match 46 PNA patients to 84 CCH patients who were simi-
lar in terms of their baseline degree of contracture and 
proportions of affected MCP joints (PNA, 34 degrees for 
41 joints versus CCH, 41 degrees for 68 joints) and affect-
ed PIP joints (PNA, 30 degrees for 26 joints versus CCH, 
35 degrees for 46 joints). All other characteristics were 
also similar between groups (Table 1, right).
Among the matched treatment groups, the average de-
gree of total extension deficit was 52 degrees. This corre-
sponded to 93% of patients being graded as Tubiana I (< 
45 degrees) or II (45–90 degrees), which indicated that the 
majority had mildly affected digits. Follow-up data were avail-
able for 91% of the primary outcome (degree of contrac-
ture), which was assessed at an average follow-up duration of 
8 weeks (range, 6–12 weeks). There were no significant dif-
ferences in baseline characteristics between those who did 
and did not have primary outcome data available (see table, 
Supplementary Digital Content 1, which displays character-
istics of the matched treatment groups, divided by those 
with (respondent) and without data (nonrespondents) 
available on the primary outcome (degree of contracture), 
http://links.lww.com/PRSGO/A527). Sixty percentage of PNA 
patients and 72% of CCH patients completed the MHQ to 
such an extent that the baseline overall score could be cal-
culated. Of these, 64% in the PNA group and 76% in the 
Fig. 1. Patient selection flowchart. lF, limited fasciectomy; PS, propensity score.
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CCH group had follow-up data available. We found no sig-
nificant differences in the baseline characteristics between 
those with and without MHQ follow-up data.
Change in Angular Correction
For affected MCP joints, the improvement in contrac-
ture at follow-up was not significantly different among the 
matched treatment groups, in percentage correction and 
in absolute degrees (Fig. 2A, B). The proportion of MCP 
joints reaching clinical improvement, defined as an im-
provement of ≥ 50% in the degree of contracture, was also 
similar between the treatment groups (Fig. 2C).
For affected PIP joints, improvement in contracture 
was also not significantly different among the matched 
treatment groups (Fig. 3A). Consistently, improvement in 
contracture in degrees was similar (Fig. 3A, B). The pro-
portion of clinically improved PIP joints in the CCH group 
was not significantly different between groups (Fig. 3C).
Adverse Effects
No serious adverse effects occurred in either of the 
matched treatment groups (Table 2). Three of the most 
common mild adverse effects in the CCH group were pe-
ripheral edema, contusion, and transient pain. The only 
Table 1. Characteristics of Clostridium Collagenase Histolyticum and PNA Treatment Groups, Before and After Propensity 
Score–Based Matching*
Treatment
Unmatched Matched
PNA (n = 51) CCH (n = 104) P PNA (n = 46) CCH (n = 84) P
Demographics      
  Age (y) 65 ± 8 61 ± 10 0.021 63 ± 8 64 ± 8 0.466
  Men (%) 65 80 0.050 72 75 0.686
  Alcohol use (%) 73 59 0.092 72 60 0.232
  Current smoker (%) 18 16 0.839 15 18 0.701
  Epilepsy (%) 0 2 1.000 0 2 0.539
Disease characteristics       
  Tubiana (%)   0.315   0.562
  Grade I 33 47  51 42  
  Grade II 53 45  45 50  
  Grade III or IV 14 8  4 6  
  Recurrent disease (%) 22 26 0.550 22 21 0.840
  Positive family history (%) 43 54 0.210 41 48 0.489
Outcomes       
  Extension deficit (degrees)       
  Total 62 ± 30 52 ± 29 0.053 49 ± 23 54 ± 30 0.317
  MCP joint level       
  All joints 39 ± 23 29 ± 24 0.010 31 ± 21 33 ± 24 0.518
  Affected joints (%) 90 75 0.026 89 81 0.226
  PIP joint level       
  All joints 20 ± 21 22 ± 25 0.498 17 ± 19 19 ± 22 0.546
  Affected joints (%) 63 61 0.795 63 57 0.513
  Distal interphalangeal joint level       
  All joints 3 ± 9 1 ± 4 0.063 1 ± 5 1 ± 5 0.966
  Affected joints (%) 14 6 0.093 9 7 0.751
*Plus-minus values are means ± SD.
MCP, metacarpophalangeal; PIP, proximal interphalangeal.
Fig. 2.  improvement in contracture for affected McP joints (a and B) and proportion of joints with clini-
cal improvement (c) among the matched ccH and PNa groups at early follow-up.
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events occurring in both treatment groups were skin fis-
sures and sensory disturbances, which did not significantly 
differ in their relative incidence between groups (P =0.491 
and P = 1.000, respectively).
Changes in Hand Function
The overall MHQ score was similar at baseline in 
the matched PNA and CCH groups. At an average of 
11 months follow-up, patients also reported a similar im-
provement in the overall score (PNA, 5.3 points versus 
CCH, 4.9 points; P = 0.912).
There were, however, differences between the 2 groups 
in the extent to which several subdomain scores improved. 
PNA patients as compared with CCH patients reported, 
on average, larger improvements in the MHQ subscores of 
satisfaction (18 points) and hand appearance (8 points), 
although only the difference in the satisfaction subscore 
reached significance (Fig. 4). CCH patients, in turn, re-
ported significantly larger improvements in the activities 
in daily life subscore (4 points). Further exploring these 
differences, all subdomain scores in absolute terms were 
similar between-groups at baseline and follow-up with the 
exception that the satisfaction and appearance subscores 
were an average of 7 and 9 points, respectively, lower in the 
PNA group than in the CCH group at baseline (P = 0.204 
and P = 0.057, respectively).
DISCUSSION
Despite the large number of studies describing the out-
comes of various treatments for Dupuytren’s contracture, 
scarce evidence is available to guide decision-making in 
the disease.26,27 The aim of this study involving multiple 
practice sites in the Netherlands was to assess the out-
comes of PNA versus CCH in clinical practice. We found 
Fig. 3. improvement in contracture for affected PiP joints (a and B) and proportion of joints with clinical 
improvement (c) among the matched ccH and PNa groups at early follow-up.
Table 2. Adverse Effects in the Matched Treatment Groups, 
by Severity Grade*
Adverse Effect PNA (n = 46) CCH (n = 84)
Mild   
Peripheral edema NA 70
Contusion NA 62
Mild NA 54
Severe NA 8
Pain NA 31
Blood blister NA 11
Axillary tenderness NA 8
Skin fissure 4 8
Sensory disturbance 2 1
Pruritus NA 4
Erythema NA 4
Lymphadenopathy NA 1
Scar sequelae 0 0
Wound healing problems 0 0
Serious 0 0
Nerve laceration   
Uncorrectable contracture 0 0
Wound infection 0 0
Arterial laceration 0 0
Tendon rupture 0 0
Cold intolerance 0 0
CRPS 0 0
*Values are percentages.
CRPS, complex regional pain syndrome; NA, not assessed. 
Fig. 4. change in MHQ scores in the matched clostridium collage-
nase histolyticum and PNa treatment groups.
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that, among patients with mild contractures (93% Tu-
biana I or II), improvement in contracture with PNA as 
compared with CCH was similar for affected MCP and 
PIP joints. No major adverse effects occurred in any of the 
2 treatment groups. Over time, the overall MHQ score 
also improved to a similar extent in both groups.
As evidenced by both the relative improvement and 
in absolute degrees, the level of contracture correction 
achieved in our study at the MCP joint level after CCH 
was similar to that after PNA. Two previous clinical trials 
reported similar findings.8,9 In the present study, affected 
MCP joints improved by 31 and 26 degrees after CCH and 
PNA, respectively. This agrees well with the similar degree 
of improvement reported by Scherman et al.8 (46 and 
47 degrees for CCH and PNA at 3 months, respectively) 
and by Strömberg et al.9 (48 and 46 degrees, respectively). 
The smaller improvement in contracture in absolute terms 
in our study can be explained by differences in baseline 
severity of contracture among the study samples as well as 
differences in assessment methods (passive versus active 
goniometry). Affected PIP joints in our study improved 
by 17 and 16 degrees after CCH and PNA, respectively. 
In comparison, Scherman et al.8 reported in their study 
that PIP joints also improved to a similar extent (8 and 
11 degrees after CCH and PNA, respectively). Again, the 
difference in absolute improvement can be explained by 
slight differences in patient inclusion. Collectively, these 
findings show that the effectiveness of CCH at reducing 
contractures is similar to that of PNA in actual clinical 
practice, despite that decision-making processes and com-
pliance in this study probably differed from that in previ-
ous clinical trials. We therefore believe that they are an 
addition to the evidence-base available on CCH and PNA.
We found no serious adverse effects following either 
treatments, which is consistent with what has previously 
been reported.9 Skin fissures and sensory disturbances 
were the only mild adverse effects that occurred after both 
CCH and PNA but were rare. All other minor effects were 
unique to the CCH group among which peripheral ede-
ma, contusion, and pain in the extremity were the 3 most 
common. We believe that these findings primarily high-
light the different modes of action of the 2 treatments.
During the first year after treatment, we found that 
the overall MHQ score improved to a similar extent af-
ter PNA and CCH. This underscores the effectiveness of 
both treatments at improving hand function for patients, 
even for those with mild contractures. Interestingly, the 
subdomain scores of satisfaction and appearance showed 
larger improvements after PNA than after CCH at follow-
up, whereas the scores in absolute terms were similar. We 
feel that this is due to the comparatively lower scores in 
these subdomains in the PNA group at baseline. Consider-
ing that both treatment groups were similar with respect 
to their baseline characteristics, including demographics 
and disease severity, this suggest less satisfaction and more 
concern with the appearance of their hands among those 
opting for PNA. Further research is warranted in this area, 
which we believe can address a knowledge gap regarding 
the concerns and needs that influence treatment decision-
making among patients with Dupuytren’s disease.28–30
The resources required for CCH and PNA may also be 
important to consider when deciding between the 2 treat-
ments, particularly considering that associated costs can 
differ substantially. Although these will vary depending on 
geographic region, the direct costs of CCH will be higher in 
most settings due to the low material costs of PNA. In addi-
tion, 2 visits are required with CCH, whereas PNA requires 
only a single visit. CCH may therefore be regarded as the 
least cost-effective option of the 2, which then ought to be 
justified by objective advantages (i.e., superior outcomes). To 
date, we are unaware of any study showing these advantages. 
Previous economic evaluations have, however, underlined 
the complexity in comparing the cost-effectiveness of differ-
ent treatments in Dupuytren’s disease due to the lack and 
quality of existing literature.27,31 The data presented in the 
current study allow for refining such economic models that 
help to identify treatment algorithms for Dupuytren’s con-
tracture that are both cost-effective and broadly applicable.
Our study has several strengths. First, it used prospec-
tive data from 7 practice sites that were gathered as part 
of daily clinical practice, making it a comparative effective-
ness study.32 The results from such studies, compared with 
strictly controlled trials, may be more broadly generalizable 
because they better reflect the actual decision-making pro-
cesses, patient compliance, and, ultimately, the outcomes 
achieved in daily practice.10,32,33 Second, we examined the 
relative change in MHQ scores rather than a cross-sectional 
assessment, which enabled a comparison of the impact of 
CCH and PNA on different aspects of hand function.34 Oth-
er strengths include the relatively large sample analyzed, 
completeness of outcome data (91% primary outcome), and 
the use of propensity scores to minimize the risk of bias due 
to observed differences. Despite this study design, a poten-
tial limitation of this study is that propensity analyses cannot 
account for selection bias related to unmeasured charac-
teristics (i.e., genetic constitution). A second limitation is 
that we could not reliably assess rates of recurrence, which 
may be as relevant to patients in treatment decision-making 
as early outcomes, because of the limited time-horizon of 
our study.30 Third, only a subset of patients completed the 
MHQ. Although this might have influenced our results, the 
possibility for attrition bias seems small because there were 
no differences in the characteristics between those who did 
and did not complete the MHQ at follow-up. Finally, the 
rare incidence of adverse effects in both treatment groups 
precludes strong inferences to be made about the compara-
tive risk profile of both treatments.
In conclusion, we found that, among patients with 
mildly affected digits, CCH and PNA were similarly ef-
fective at improving contractures. Even among these pa-
tients, we found a significant and similar improvement in 
overall hand function, which reinforces the usefulness of 
both treatments as first-line treatments. Our findings also 
underscore the safety of both techniques in daily practice. 
Until longer term studies are conducted that are urgently 
needed to better understand the durability of the out-
comes of both treatments, we believe that these findings 
may help patients with Dupuytren’s disease, payers and 
providers decide between these 2 minimally invasive treat-
ment options.
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